Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 5/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.47 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 3/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10198825 | 0.89 | CHEK1 (0.50) | MTORPIK3CAPIK3R1SMN1; SMN2KDM4E | |
| SCHEMBL3326043 | 0.88 | LMNA (0.58) | SMN1; SMN2MAPK1LMNAKDM4EALDH1A1 | |
| SCHEMBL3324581 | 0.85 | PIK3CA (0.49) | MTORPIK3CAPIK3R1SMN1; SMN2MAPK1 | |
| SCHEMBL14259010 | 0.84 | LMNA (0.56) | SMN1; SMN2MAPK1LMNAKDM4EALDH1A1 | |
| SCHEMBL13759202 | 0.78 | ADORA3 (0.48) | SMN1; SMN2MAPK1LMNAKDM4EALDH1A1 | |
| SCHEMBL1643932 | 0.78 | ADORA2A (0.51) | SMN1; SMN2MAPK1LMNAKDM4EALDH1A1 | |
| SCHEMBL10196890 | 0.78 | CHEK1 (0.47) | SMN1; SMN2MAPK1LMNAKDM4EALDH1A1 | |
| SCHEMBL3326178 | 0.77 | LMNA (0.59) | SMN1; SMN2MAPK1LMNAKDM4EALDH1A1 | |
| SCHEMBL10198823 | 0.77 | KMT2A (0.61) | SMN1; SMN2MAPK1LMNAKDM4EALDH1A1 | |
| SCHEMBL3326864 | 0.76 | MAPT (0.61) | SMN1; SMN2MAPK1LMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-13 | — | — | US | disclosed |
| US-7410990-B2 | Heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2008-08-12 | — | — | US | disclosed |
| US-7410990-B2 | Heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070027151-A1 | Heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027151-A1 | Heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | IL17A, IL23R, IL15 | MTOR 3123/4885PIK3CA 2168/4885PIK3R1 1886/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | MTOR 3130/4885PIK3CA 4463/4885PIK3R1 1308/4885 |
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | BRCA1, VHL, ESR1 | MTOR 780/4885PIK3CA 386/4885PIK3R1 1957/4885 |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | BRCA1, VHL, ESR1 | MTOR 780/4885PIK3CA 386/4885PIK3R1 1957/4885 |
| US-20070027151-A1 | Heterocyclic compounds | NRAS, OXER1, HCRTR2 | MTOR 1741/4885PIK3CA 3455/4885PIK3R1 1496/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | MTOR 3130/4885PIK3CA 4463/4885PIK3R1 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.